Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes

详细信息    查看全文

• 作者：Huiyun Pan (1)
  Rong Liu (1)
  Shengjie Li (1)
  Hui Fang (1)
  Ziwei Wang (1)
  Sheng Huang (2)
  Jianying Zhou (3)
  
• 关键词：Icotinib ; Non ; small lung cancer ; EGFR mutation
• 刊名：Cell Biochemistry and Biophysics
• 出版年：2014
• 出版时间：September 2014
• 年：2014
• 卷：70
• 期：1
• 页码：553-558
• 全文大小：407 KB
• 参考文献：1. Aberle, D. R., & Brown, K. (2008). Lung cancer screening with CT. / Clinics in Chest Medicine, / 29(1), 1-4. CrossRef
  2. Hua, X., Ward, K. C., Gillespie, T. W., Lipscomb, J., & Goodman, M. (2013). Non-small cell lung cancer treatment receipt and survival among African–Americans and whites in a rural area. / Journal of Community Health, / 2013, 1-0.
  3. Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. / The New England Journal of Medicine, / 346(2), 92-8. CrossRef
  4. Robert, C., Soria, J. C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P., et al. (2005). Cutaneous side-effects of kinase inhibitors and blocking antibodies. / The lancet Oncology, / 6(7), 491-00. CrossRef
  5. Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., et al. (2013). EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. / International Journal of Medical Sciences, / 10(3), 320-30. CrossRef
  6. Lee, C. K., Brown, C., Gralla, R. J., Hirsh, V., Thongprasert, S., Tsai, C. M., et al. (2013). Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. / Journal of the National Cancer Institute, / 105(9), 595-05. CrossRef
  7. Iivanainen, E., Lauttia, S., Zhang, N., Tvorogov, D., Kulmala, J., Grenman, R., et al. (2009). The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. / Microvascular Research, / 78(3), 278-85. CrossRef
  8. Dongiovanni, D., Daniele, L., Barone, C., Dongiovanni, V., Fissore, C., Sapino, A., et al. (2008). Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)? / Lung Cancer, / 61(1), 73-1. CrossRef
  9. Chen, L., He, Y., Huang, H., Liao, H., & Wei, W. (2008). Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. / Medical Oncology, / 25(2), 161-71. CrossRef
  10. Razis, E., Skarlos, D., Briasoulis, E., Dimopoulos, M., Fountzilas, G., Lambropoulos, S., et al. (2005). Treatment of non-small cell lung cancer with gefitinib (‘Iressa- ZD1839): the Greek experience with a compassionate-use program. / Anti-Cancer Drugs, / 16(2), 191-98. CrossRef
  11. Tan, F., Shen, X., Wang, D., Xie, G., Zhang, X., Ding, L., et al. (2012). Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. / Lung Cancer, / 76(2), 177-82. CrossRef
  12. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. / The New England Journal of Medicine, / 350(21), 2129-139. CrossRef
  13. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. / Science, / 304(5676), 1497-500. CrossRef
  14. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., et al. (2004). EGF receptor gene mutations are common in lung cancers from “never smokers-and are associated with sensitivity of tumors to Gefitinib and Erlotinib. / Proceedings of the National Academy of Sciences of the United States of America, / 101(36), 13306-3311. CrossRef
  15. Gandhi, J., Zhang, J., Xie, Y., Soh, J., Shigematsu, H., Zhang, W., et al. (2009). Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. / PLoS ONE, / 4(2), e4576. CrossRef
  16. Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., et al. (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. / The Lancet Oncology, / 11(2), 121-28. CrossRef
  17. Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., et al. (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. / The New England Journal of Medicine, / 362(25), 2380-388. CrossRef
  18. Shi, Y., Zhang, L., Liu, X., Zhou, C., Zhang, S., Wang, D., et al. (2013). Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. / The Lancet Oncology, / 14(10), 953-61. CrossRef
  19. Piperdi, B., & Perez-Soler, R. (2012). Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients. / Drugs, / 72(Suppl 1), 11-9. CrossRef
  20. Fiala, O., Pesek, M., Finek, J., Benesova, L., Bortlicek, Z., & Minarik, M. (2013). Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line Erlotinib versus the reverse sequence. / Anticancer Research, / 33(8), 3397-402.
  21. Garassino, M. C., Martelli, O., Broggini, M., Farina, G., Veronese, S., Rulli, E., et al. (2013). Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. / The lancet Oncology, / 14(10), 981-88. CrossRef
  22. Costa, D. B., & Kobayashi, S. (2007). Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different? / British Journal of Cancer, / 96(2), 399. CrossRef
  23. Wu, J. Y., Yu, C. J., Yang, C. H., Wu, S. G., Chiu, Y. H., Gow, C. H., et al. (2008). First- or second-line therapy with Gefitinib produces equal survival in non-small cell lung cancer. / American Journal of Respiratory and Critical Care Medicine, / 178(8), 847-53. CrossRef
  24. Ruppert, A. M., Beau-Faller, M., Neuville, A., Guerin, E., Voegeli, A. C., Mennecier, B., et al. (2009). EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. / The European Respiratory Journal, / 33(2), 436-40. CrossRef
  
• 作者单位：Huiyun Pan (1)
  Rong Liu (1)
  Shengjie Li (1)
  Hui Fang (1)
  Ziwei Wang (1)
  Sheng Huang (2)
  Jianying Zhou (3)
  
  1. Gerontology Center, The First Affiliated Hospital, Zhejiang University, No. 79, Qingchun Road, Hangzhou, 310003, Zhejiang, China
  2. Respiratory Department, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005, Zhejiang, China
  3. Respiratory Department, The First Affiliated Hospital, Zhejiang University, No. 79, Qingchun Road, Hangzhou, 310003, Zhejiang, China
  
• ISSN：1559-0283

文摘

Icotinib is the first oral epidermal growth factor receptor (EGFR) tyrosine kinase receptor inhibitor, which has been proven to exert significant inhibitory effects on non-small cell lung cancer in vitro. Clinical evidence has showed that the efficacy of Icotinib on retreating advanced non-small cell lung cancer is comparable to Gefitinib. However, different phenotypes of EGFR can affect the therapeutic outcomes of EGFR tyrosine kinase receptor inhibitor. Therefore, our study focused on efficacy and safety of Icotinib in patients with advanced non-small cell lung cancer of different EGPR phenotypes. Clinical data of patients with advanced non-small cell lung cancer who received Icotinib treatment from August, 2011 to May, 2013 were retrospectively analyzed. Kaplan–Meier analysis was used for survival analysis and comparison. 18 wild-type EGFR and 51 mutant type were found in a total of 69 patients. Objective response rate of patients with mutant type EGFR was 54.9?% and disease control rate was 86.3?%. Objective response rate of wild-type patients was 11.1?% (P?=?0.0013 vs mutant type), disease control rate was 50.0?% (P?=?0.0017). Median progression-free survival (PFS) of mutant type and wild-type patients were 9.7?and 2.6?months, respectively (P?P?=?0.3145). Median overall survival (OS) of EGFR mutated patients had not reached. OS time of 13 wild-type patients was 12.9?months (P?EGFR mutated patients, making it an optimal regimen to treat EGFR mutated patients. Furthermore, most of adverse reactions associated with Icotinib treatment were tolerable.